高血糖与前列腺癌中的微小RNA
本研究检测了105例前列腺癌患者和138例非癌对照者尿液中7种微小RNA的相对表达,并结合空腹血糖分析。结果显示,高血糖非癌对照者中miR-200b-3p、miR-187-3p、miR-182-5p和miR-100-5p显著下调;高血糖前列腺癌患者较未治疗高血糖对照者miR-375和miR-182-5p达3倍变化。作者认为高血糖可持续促进miR-375和miR-182-5p表达。
要点
- 高血糖非癌对照者中miR-200b-3p、miR-187-3p、miR-182-5p和miR-100-5p显著下调。
- 高血糖前列腺癌患者较未治疗高血糖对照者miR-375和miR-182-5p达3倍变化。
- 作者认为未控制的高血糖状态可能通过促进基因表达为前列腺癌发展创造适宜微环境。
核心结论
- 微小RNA失调可发生于高血糖前列腺癌患者,相较于未治疗高血糖的非癌对照者。
- 高血糖可持续促进miR-375和miR-182-5p的表达。
- 未控制的高血糖状态可能通过促进基因表达为日后前列腺癌发展创造适宜微环境。
研究设计与样本
- 采用实时定量PCR检测105例前列腺癌患者和138例非癌对照者尿液中miR-574-3p、miR-375、miR-205-5p、miR-200b-3p、miR-187-3p、miR-182-5p和miR-100-5p的相对表达。
- 空腹血浆血糖值取自临床记录。
- 组间微小RNA差异表达采用非参数检验比较,与血糖和前列腺特异性抗原(PSA)的相关性采用Pearson相关系数检验。
主要发现
- 按血糖状态分析,高血糖非癌对照者中miR-200b-3p、miR-187-3p、miR-182-5p和miR-100-5p显著下调,其中miR-187-3p、miR-182-5p和miR-100-5p下调幅度最低。
- 高血糖前列腺癌患者较未治疗高血糖对照者所选微小RNA显著失调,其中miR-375和miR-182-5p达3倍变化。
- 无论血糖状态如何,前列腺癌患者仅观察到miR-574-3p下调;血糖正常前列腺癌患者中仅见miR-574-3p、miR-200b-3p、miR-187-3p和miR-182-5p轻度下调。
- 对照者中检测到微小RNA与血糖(miR-200b-3p、miR-100-5p)及PSA(miR-205-5p、miR-187-3p)显著相关;前列腺癌患者中miR-205-5p和miR-187-3p与血糖相关,而miR-574-3p和miR-375呈反向关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperglycemia can promote the development of prostate cancer (PCa). Differential expression levels of miRNAs between PCa patients and controls were also reported. Therefore, we examined the relationship between hyperglycemia and miRNA levels in PCa. METHODS: Relative expression of urinary miR-574-3p, miR-375, miR-205-5p, miR-200b-3p, miR-187-3p, miR-182-5p, and miR-100-5p were investigated in 105 PCa patients and 138 noncancer controls by Real-Time quantitative PCR. Fasting plasma glucose measurements were retrieved from clinical records. The differential miRNA expressions among groups were compared using non-parametric tests. Correlations with glucose and prostate-specific antigen (PSA) were tested using Pearson correlation coefficient. RESULTS: When we analyzed miRNA expression according to glycemic state, significant down-regulations were found for miR-200b-3p, miR-187-3p, miR-182-5p, and miR-100-5p in noncancer controls with high glucose. The lowest down-regulations were observed for miR-187-3p, miR-182-5p, and miR-100-5p. Subsequently, when hyperglycemia was considered in PCa, significant dysregulations of selected miRNAs were found in hyperglycemic PCa patients than in controls with high glucose. In particular, miR-375 and miR-182-5p showed a 3-FC in hyperglycemic PCa patients than controls who left hyperglycemia untreated. Conversely, only a down-regulation of miR-574-3p was observed in PCa patients regardless of glycemic status and only modest down-regulation of miR-574-3p, miR-200b-3p, miR-187-3p and miR-182-5p were found in normoglycemic PCa patients. Next, significant correlations between miRNAs and glucose (miR-200b-3p, miR-100-5p) and PSA (miR-205-5p and miR-187-3p) were detected in controls. Similarly, miR-205-5p and miR-187-3p were correlated with glucose in PCa patients, while miR-574-3p and miR-375 showed inverse relationships. CONCLUSIONS: miRNA dysregulations can occur in hyperglycemic PCa patients as compared to noncancer controls who left hyperglycemia untreated. Hyperglycemia can consistently promote the expression of miR-375 and miR-182-5p. Uncontrolled hyperglycemic state could contribute to the creation of a suitable microenvironment for later PCa development by promoting gene expression.
引用
- Russo V, Tamburrino L, Morselli S, et al. Hyperglycemia and microRNAs in prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38402304. doi:10.1038/s41391-024-00809-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。